Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.
A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
Research Roundup: Major Breakthrough in HIV Research and MoreAustralia, China, Coronavirus Disease 2019 (COVID-19), Drug Cocktails, Genes, Genetic Markers, Genomes, Germany, Herpes Simplex Virus, HIV, Immune Cells, Medical Journals, Mount Sinai, Neurodegenerative Diseases, New England Journal of Medicine, Nucleotides, R&D, RNA, San Francisco (UCSF), Science, Scientific studies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), The Netherlands, Thrombosis Research, University of Alabama at Birmingham (UAB), University of Maryland Baltimore County, Walter and Eliza Hall Institute
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
The immuno-oncology therapy CAR-T utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
Researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key switch that has the potential to eliminate dormant HIV reservoirs.
Merck Acquires Immune DesignAcquisitions, Business, Cancer, Cellular immunotherapy, Cellular immunotherapy, Chronic Diseases, Collaborations, Health Technology, Immune Cells, Immune System, Immunizations, Intratumoral TLR4 agonists, Investigational New Drug (INDs) submissions, Oncology, Sarcomas, Shares, Synovial sarcoma, T-Cells
Shares of Immune Design skyrocketed after Merck announced the acquisition of the Seattle-based oncology company for $300 million in cash.
Privately held Tizona Therapeutics snagged $105 million in upfront cash as the company’s cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.
Health authorities in England agreed with Novartis to fast-track access to the Swiss drugmaker’s expensive CAR-T cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed.
A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said.
U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than double the previous year — while the figure also rose in the EU.